PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02.

On April19, 2017, the Board of Directors (the Board) of Provectus
Biopharmaceuticals, Inc. (the Company) retained Bruce Horowitz as
the Companys chief operations consultant.

Mr.Horowitz, 61, is a member of the Board and has served as the
Managing Director of Capital Strategists, LLC, which provides
corporate, strategic, and financial consulting services, since
September 2006. He also serves as a trusted advisor to family
trusts and private individuals, with a focus on financial asset
management, real estate management and special situation
investments. Earlier in his career Mr.Horowitz was a charter
member of the New York Futures Exchange, a Senior Vice President
managing principal equity investment accounts, private equity
investments and public offerings at Drake Capital Securities, and
managed the trading department at Laidlaw Equities. He was also a
partner at Stanley Capital, a private equity buyout firm.
Mr.Horowitz was the chairman and a member of two general
obligation bond fund committees, raising more than $500 million
in general revenue bonds for the Beverly Hills Unified School
District. Subsequently, he was named the first chairman of both
the state of California-mandated Citizens Oversight Committee and
Facilities Advisory Committee, overseeing expenditure of all
BHUSD general obligation bond funds. Mr.Horowitz is a founding
member of the Los Angeles Chapter of the Positive Coaching
Alliance. He founded and is currently the president of the
Beverly Hills Basketball League, a youth basketball program that
serves more than 35,000 families. Mr.Horowitz has also served as
a member of the board of directors of the American Youth Soccer
Organization and Beverly Hills Little League. He holds a Juris
Doctor degree from Benjamin N. Cardozo School of Law in New York
City and Bachelor of Arts degree from Washington University in
St. Louis.

Mr.Horowitz does not have a family relationship with any of the
current officers or directors of the Company. As previously
disclosed by the Company in a Current Report on Form 8-K, filed
with the Securities and Exchange Commission (the Commission) on
March23, 2017, the Company entered into an exclusive Definitive
Financing Commitment Term Sheet effective as of March19, 2017,
which sets forth the terms on which a group of the Companys
stockholders, including Mr.Horowitz, will provide financing to
the Company.

In connection with the engagement of Mr.Horowitz, on April19,
2017, the Company and Mr.Horowitz entered into an independent
contractor agreement (the Agreement), to which Mr.Horowitz will
serve as the primary business operations consultant of the
Company and will perform duties and services including but not
limited to designing and implementing new business strategies and
plans, and operating processes and procedures; establishing
policies to promote a new company culture; overseeing company
operations and the work of executives, managers, and staff
members; prioritizing and continuing the Companys search for a
Chief Medical Officer and a new Chief Executive Officer;
assisting in fundraising activities; and managing certain partner
and vendor relationships. In consideration for such services,
Mr.Horowitz will be paid $125 per hour, up to a maximum of
$20,000 in a calendar month. The Company will reimburse
Mr.Horowitz for all reasonable and necessary expenses relating to
his provision of services under the Agreement. The initial term
of the Agreement is from April1, 2017 to June30, 2017, and
thereafter will continue on a month-to-month basis unless
terminated by either party upon 30 days prior written notice.

The Company agreed to indemnify Mr.Horowitz and Capital
Strategists, LLC for claims made against Mr.Horowitz based upon
the performance of his services. The Agreement contains customary
confidentiality, customer non-solicitation, and employee
non-solicitation provisions.

1

The foregoing description of the Agreement does not purport to be
complete and is qualified in its entirety by reference to the
Agreement, a copy of which is filed as Exhibit 10.1 to this
Current Report on Form8-K.

On April20, 2017, the Company issued a press release (the Press
Release) announcing the reestablishment of the Companys Strategic
Advisory Board, the appointment of Ed Pershing as the Strategic
Advisory Board Chairman and an observer of the Board and all
Board committees (serving all exclusively in an advisory capacity
only), and the retention of Mr.Horowitz as chief operations
consultant. A copy of the Press Release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.

to the rules and regulations of the Commission, the information
in this Item7.01 disclosure, including Exhibit 99.1 and
information set forth therein, is deemed to have been furnished
and shall not be deemed to be filed under the Securities Exchange
Act of 1934, as amended.

2

About PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT)

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Recent Trading Information

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) closed its last trading session down -0.0021 at 0.0380 with 1,307,513 shares trading hands.